Vivanza Biosciences Reports Mixed Financial Results Amid Sales Growth and Declining Profitability in August 2025

Vivanza Biosciences, a microcap company in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending June 2025. The results, declared on August 13, 2025, indicate a notable shift in the company's evaluation, with the score adjusting to -4 from -7 over the past three months. The financial data reveals that Vivanza Biosciences achieved its highest quarterly net sales in the last five quarters, reaching Rs 8.94 crore. This positive sales trend suggests a potential for growth in the near term. However, the company faces challenges as its Profit After Tax (PAT) for the quarter stands at Rs 0.09 crore, reflecting a significant decline of 66.7% year on year. This negative trend in PAT indicates underlying issues that may need to be addressed. Additionally, the Debtors Turnover Ratio has reached its lowest point in the last five half-yearly periods at 0.92 times, suggesting a slowdown in the company's ability to settle its debts. Overall, while there are positive indicators in sales, the financial results highlight areas of concern for Vivanza Biosciences. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.